AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie (ABBV) Stock Falls After $63 Billion Allergan Acquisition Announcement
by Zachary Stutler
AbbVie announced Tuesday morning its intent to acquire Allergan for $63 billion.
Abbvie Decides to Acquire Allergan
by Zacks Equity Research
Abbvie Decides to Acquire Allergan
AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
by Mark Vickery
AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.
AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study
by Zacks Equity Research
AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.
Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $78.45 in the latest trading session, marking a -0.42% move from the prior day.
Forget Bargain Hunting: Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
by Zacks Equity Research
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
by Zacks Equity Research
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Top Ranked Income Stocks to Buy for June 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 21st.
Is AbbVie (ABBV) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bayer to Invest 5 Billion Euros in Weedkiller Research
by Zacks Equity Research
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $78.60, marking a -0.11% move from the previous day.
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
by Zacks Equity Research
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
by Zacks Equity Research
Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Top Ranked Income Stocks to Buy for June 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 17th.
3 Big Pharma Stocks to Buy Right Now
by Zachary Stutler
These big pharma stocks all have a Zacks Rank #2 or better.
Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
by Zacks Equity Research
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
by Zacks Equity Research
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
by Zacks Equity Research
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $76.95 in the latest trading session, marking a -0.62% move from the prior day.
Top Ranked Growth Stocks to Buy for June 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 10th
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
by Zacks Equity Research
AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
by Zacks Equity Research
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix